Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry
https://doi.org/10.14412/1996-7012-2021-1-27-31
Abstract
The goal of psoriatic arthritis (PsA) therapy is to achieve remission or minimal disease activity (MDA). According to the EULAR guidelines, synthetic disease-modifying antirheumatic drugs (sDMARDs), methotrexate (MTX) in particular, are first-line therapy for PsA.
Objective: to study the rate of MDA achievement after initiation of sDMARD therapy in patients with early- and late-stage PsA and the efficacy of oral and parenteral MTX.
Patients and methods. The investigation enrolled 253 patients (93 men and 160 women) diagnosed with PsA who met the appropriate 2006 CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria and were recorded in the All-Russian PsA Registry. The median (Me) age was 47 (Min 20 – Max 82) years. All the patients took sDMARDs: MTX (n=211) that was received orally (as tablets) (n=102) and parenterally (n=109); leflunomide (n=7); sulfasalazine (n=24); apremilast (n=10); and tofacitinib (n=1). According to the disease duration at sDMARD treatment initiation, the patients were divided into two groups. Group 1 included 165 patients with an early PsA duration of less than 2 years and Group 2 consisted of 88 patients with a disease duration of >2 years. The efficiency of oral and parenteral MTX was evaluated in 182 patients (68 men and 114 women). Every 6 months, the patients underwent a standard rheumatology examination that included PsA activity assessment. The efficiency of MTX therapy was evaluated from MDA achievement (5 out of the 7 criteria) in the patients.
Results and discussion. After sDMARD prescription, MDA was achieved in 39 (24%) of the 165 patients with early PsA and in 4 (5%) of the 88 long-term patients. The patients who started sDMARD at an early stage of the disease were significantly more likely to achieve MDA than those with late-stage PsA (odds ratio (OR) 6.5; 95% confidence interval (CI) 2.2–18.9). At 11 years after sDMARD therapy initiation, the cumulative MDA achievement rate in the patients with late-stage disease was 5% (p<0.05). MDA was achieved by 16.5% of the 182 patients receiving oral or subcutaneous MTX. MDA was observed in 25 (31%) patients who received parenteral MTX and in only 5 (5%) patients who took oral MTX. The patients who received parenteral MTX were significantly more likely to achieve MDA than those who took oral MTX as tablets (OR 8.8; 95% CI 3.2–24.3). Following 27-month parenteral MTX therapy, the cumulative rate of MDA achievement was 48%, whereas after oral MTX treatment, that was 7% (p<0.05). In the patients who achieved MDA, the mean dose of parenteral MTX was 17 mg/week, and in those who failed, that was 15 mg/week. The mean dose of oral MTX was 15 mg/week, regardless of MDA achievement.
Conclusion. The administration of sDMARD at an early stage of PsA lasting less than 2 years allows MDA to be achieved significantly more often and faster than at later stages of the disease. Among sDMARDs, preference is mostly given to the use of MTX in real clinical practice; the treatment with the latter enables 16.5% of patients to achieve MDA. Parenteral MTX significantly enhances the efficiency of therapy and can achieve MDA in almost one third (31%) of patients.
Keywords
About the Authors
T. V. KorotaevaRussian Federation
Tatiana Viktorovna Korotaeva
34A, Kashirskoe Shosse, Moscow 115522
E. Yu. Loginova
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. E. Gubar
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Yu. L. Korsakova
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. V. Sedunova
Russian Federation
30, Bolshaya Pod'yacheskaya St., Saint Petersburg 190068
I. N. Pristavsky
Russian Federation
30, Bolshaya Pod'yacheskaya St., Saint Petersburg 190068
I. N. Kushnir
Russian Federation
22, Oktyabrsky Prospect, Kemerovo 650000
I. F. Umnova
Russian Federation
3, Berezovaya St., Omsk 644111
S. S. Kudishina
Russian Federation
57, Russkaya St., Vladivostok 690105
References
1. Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian clinical guidelines]. Moscow: GEOTAR-Media; 2017. 456 p.
2. Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011 Dec;70(12):2152-4. doi: 10.1136/ard.2011.150938. Epub 2011 Sep 12.
3. Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favorable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407-13. doi: 10.1136/annrheumdis-2012-201972.
4. Korotaeva TV, Loginova EYu, Getiya TS, Nasonov EL. Results of the use of the strategy «Treatment to achieve the goal» in patients with early psoriatic arthritis 1 year after the start of therapy: data from the REMARQUE study. Terapevticheskii arkhiv. 2018;90(5): 22-9. (In Russ.).
5. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.
6. Huynh DH, Boyd TA, Etzel CJ, et al. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open. 2017 Jan 16;3(1):e000395. doi: 10.1136/rmdopen-2016-000395. eCollection 2017.
7. Loginova EYu, Korotaeva TV, Gubar' EE, et al. The effect of the duration of psoriatic arthritis on the achievement of remission and minimal activity of the disease against the background of therapy with genetically engineered biological drugs. Data of the All-Russian Register of patients with psoriatic arthritis. Nauchnoprakticheskaya revmatologiya. 2020;58(6): 695-700. (In Russ.).
8. Loginova EYu, Korotaeva TV, Korsakova YuL, et al. The clinical status and working capacity in patients included in the All-Russian Psoriatic Arthritis Registry. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(3):19-26. (In Russ.). doi: 10.14412/1996-7012-2020-3-19-26.
9. Sheane BJ, Thavaneswaran A, Gladman DD, Chandran V. Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. J Rheumatol. 2016 Sep;43(9):1718- 23. doi: 10.3899/jrheum.160111. Epub 2016 Jul 15.
10. Coates LC, Helliwell PS. Methotrexate efficacy in the Tight Control in Psoriatic Arthritis study. J Rheumatol. 2016 Feb;43(2): 356-61. doi: 10.3899/jrheum.150614. Epub 2015 Dec 15.
11. Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018 Jan 9;14:105-16. doi: 10.2147/TCRM.S154745. eCollection 2018.
12. Bianchi G, Caporali R, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016 Mar;33(3):369-78. doi: 10.1007/s12325-016-0295-8. Epub 2016 Feb 4.
13. Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016 Jun;75(6):1003-8. doi: 10.1136/annrheumdis-2014-206504. Epub 2015 May 15.
14. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019 Jul; 71(7):1112-24. doi: 10.1002/art.40851. Epub 2019 May .
Review
For citations:
Korotaeva TV, Loginova EY, Gubar EE, Korsakova YL, Sedunova MV, Pristavsky IN, Kushnir IN, Umnova IF, Kudishina SS. Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(1):27-31. https://doi.org/10.14412/1996-7012-2021-1-27-31